MedTrace Logo

Financial Toxicity and Quality of Life in Patients With TGCT

NCT04531709 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2025-07-14

No results posted yet for this study

Summary

This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.

Conditions

  • Testicular Neoplasm

Interventions

OTHER

Comprehensive Score for financial toxicity (COST)

Measure indirect and direct health care cost that burden patients and their loved ones.

OTHER

Functional Assessment of Cancer Therapy: General (FACT-G)

General quality of life instrument

OTHER

EORTC QLQ C-30

Assess quality of life in cancer patients

OTHER

EORTC QLQ-TC26.

To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Deepak Pruthi, MD · The University of Texas Health Science Center at San Antonio

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-02-04
Completion
2025-02-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531709 on ClinicalTrials.gov